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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The relationship between statin use and lung cancer remains unclear.
Patients with diabetes mellitus, who are at higher risks for both cancer and atherosclerosis,
are usually indicated for statin use. The objective was to explore the relationship between sta-
tins, lung squamous cell carcinoma (SCC), and lung adenocarcinoma incidence in diabetic pa-
tients.
Methods: A cohort of 596,812 type 2 diabetic patients was identified from the Taiwan National
Health Insurance claims database in the year 2000, and followed until the earliest of lung can-
cer diagnosis, death, or December 31, 2007. A Cox regression model with time-varying statin
use was applied to estimate the hazard ratio (HR) of lung cancer incidence comparing use
and nonuse of statins. A sensitivity analysis was applied to examine the association after
adjustment for smoking effect.t of Internal Medicine, National Taiwan University Hospital, National Taiwan University, College of
of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, 579 Yun-Lin Road,
nty 640, Taiwan.
.com (C.-Y. Chen), chiahsuin123@yahoo.com.tw (C.-H. Chang).
ight ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
3.08.002
DM, statins, smoking and lung cancer 941Results: In the original diabetic cohort, 60,969 statin users and 535,843 statin nonusers were
identified. In a median follow-up time of 7.9 years, a total of 1182 incident SCC cases and
2345 adenocarcinoma cases developed. Initial analysis showed a decreased risk of SCC if sta-
tins were ever used (HR, 0.69; 95% confidence interval, 0.60e0.81). However, the relative risk
would be 0.92 for males and 0.90 for females for statins after adjusting for smoking effect.
There was no association between statin use and adenocarcinoma (HR, 0.97; 95% confidence
interval, 0.88e1.07), with similar findings after controlling for smoking effect.
Conclusion: There is no statistically significant association between statin use with lung cancer
incidence in diabetic patients after adjustment for the confounding effect attributed to ciga-
rette smoking.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA
(HMG-CoA) reductase that have been widely used to lower
serum cholesterol levels and proven for prevention of car-
diovascular diseases.1 Due to the pleiotropic effects, sta-
tins have shown potential benefits in several diseases.2
Furthermore, given their involvement in a number of
growth-regulatory processes, statins have been suggested
as anticancer drugs.
However, the PROSPER and LIPID trials reported that
patients taking pravastatin more often developed can-
cer.3,4 By contrast, several observational studies and
meta-analysis of randomized trials did not indicate an in-
crease in overall cancer risk for statins.5,6 Among all ma-
lignancies, lung cancer is one of the most common and
lethal types. A retrospective case-control study demon-
strated that statin use was associated with a risk reduction
of lung cancer of 55%.7 It has been argued that the
beneficial effect might result from “time-window bias”
because different time lengths between cases and con-
trols are used to define time-dependent exposures. When
time was accounted for properly, no benefit of statins on
lung cancer risk is suggested.8 Similarly, in cohort studies
comparing those who have used statins at any time with
those who have not, a follow-up period during which a
study outcome cannot occur confers a spurious advantage
to the treated group.9 In case of inappropriate accounting
for follow-up time and treatment status, it may introduce
“immortal time bias”. Other potential bias includes failure
to control for important confounding factors, in particular
cigarette smoking.10
Furthermore, lung cancer comprises various cell types.
Evidence suggests that lung squamous cell carcinoma (SCC)
and adenocarcinoma have different risk factors and
respond differently to chemotherapy or target therapy.11,12
Analyses examining the relation with overall lung cancer
risk are likely to diminish the risk estimate if statin use is
associated with only one of the cell types.
Due to the controversy, we aimed to conduct a
nationwide study to illustrate the association between
statin use and lung cancer incidence (SCC and adenocar-
cinoma), taking into account immortal time bias, in the
diabetic patients, who have been regarded as a high-risk
group for cancer13,14 and also have an indication for statin
use.15Materials and methods
Data source
The Taiwan National Health Insurance (NHI) claims data-
base includes complete outpatient visits, hospital admis-
sions, prescriptions, disease, and vital status for 99% of the
population of 23 million in Taiwan. We established the
longitudinal medical history of each beneficiary by linking
several computerized claims datasets and National Cancer
and Death Registry through the civil identification number
unique to each beneficiary and birth date. The study pro-
tocol was approved by the National Taiwan University
Hospital Research Ethics Committee.Study population
Data for all patients with any diabetes diagnostic codes (The
International Classification of Diseases, 9th Revision, Clinical
Modification, ICD-9-CM code 250 and A code 181) in the
claims database between January 1, 2000 and December 31,
2000 were retrieved. An algorithm including age, number of
outpatient visits, number of hospitalizations, and the hos-
pital level was used to identify potential diabetic patients
with improved accuracy. This definition of diabetes was
evaluated by a study sampling 9000 patients with a diagnosis
of diabetes in the NHI claims data in 2000. The diagnostic
accuracy of diabetes was assessed based on patient response
to a questionnaire concerning being told by doctors to have
diabetes or ever use of hypoglycemic agents. Individuals who
gave negative or uncertain answers but were using hypo-
glycemic agents in the pharmacy claims database were also
classified as diabetic. Validation of this algorithm by which
640,173 patients were identified demonstrated 93.2% sensi-
tivity and 92.3% positive predictive value. This diabetic
cohort has been studied to examine the cancer risk of
several medications, including hypoglycemic agents and
angiotensin receptor blockers.16e18
To enroll patients aged 30e100 years with type 2 dia-
betes, we first excluded those who had insulin dependent
diabetes mellitus. Patients were further classified as having
prevalent or newly-diagnosed type 2 diabetes according to
the criteria in 1999. Patients were followed from January 1,
2000 (for prevalent type 2 diabetes patients) or the date of
diabetes diagnosis in 2000 (for newly diagnosed type 2
942 Y.-H. Dong et al.diabetes patients) to the earliest of cancer diagnosis,
death, disenrollment from the NHI, or December 31, 2007.
Assessment of statin use
The exposure of interest was use of statins, including sim-
vastatin, lovastatin, pravastatin, fluvastatin, atorvastatin,
and rosuvastatin. We collected information of prescribed
drug types, dosage, prescription date, supply days, and
total number of pills dispensed from the outpatient phar-
macy prescription database. We also calculated cumulative
treatment duration and dosage among statin users. Patients
were allowed to have a grace period of up to 30 days be-
tween prescription dates when calculating continuous
therapy. Data are presented as the number of defined daily
doses, which was established by an expert panel as the
typical maintenance daily dose for a drug prescribed for its
main indication in adults.19
Assessment of other covariates
Other medications, including hypoglycemic agents,
fibrates, low dose aspirin, and various antihypertensive
drugs were recorded. Covariate information included age,
sex, the socio-economic status (using monthly income as a
proxy), and comorbidities.
Assessment of lung cancer
All individuals in the study cohort with first occurrence of
pathologically confirmed primary lung cancer, including
SCC and adenocarcinoma, were identified. All potential
cases were validated and information about cell types was
obtained by a linkage through the National Cancer Registry.
Statistical analysis
Demographic characteristics, comorbidities, and medica-
tion use between statin users and nonusers in 2000 were
compared. For all diabetic cohort members, we computed
their follow-up person-days in individual statin. Because of
the time-varying nature of drug use and the potential cu-
mulative drug effect on lung cancer incidence in a pro-
longed duration, we defined each participant’s exposure
status as “use” at the date of first statin prescription and
this status remained unchanged until the end of follow-up.
Participants who received no stain prescription contributed
to the category of “nonuse”.
A Cox regression model with time-varying statin use and
other covariates was used to estimate the crude and
adjusted hazard ratio (HR) and 95% confidence interval (CI)
for the association between “use” of statin as a class and
individual statin and cancer occurrence with “nonuse” as
the reference group. Because drug exposure status or cu-
mulative dosage changes over time, the commonly pro-
pensity score matching method is highly complex to be
conducted and may reduce the sample size in the matching
process. Instead, the time-varying multivariate regression
analysis can provide similar risk estimates and effectively
prevent the immortal time bias in the setting.9 Potential
covariates were selected by stepwise selection withp < 0.10 for model entry and p > 0.05 for removal. The
associations between statin use and lung SCC and adeno-
carcinoma incidence were separately estimated.
In the dose- and duration-response analyses, we calcu-
lated the HRs for higher, intermediate, and lower cumula-
tive dose in terms of defined daily doses, and for
cumulative treatment duration 3 years, 2e3 years, 1e2
years, and 1 year. Additionally, subgroup analyses were
performed to evaluate potential effect modification. Dia-
betic patients were stratified according to: (1) newly-
diagnosed or prevalent diabetes; (2) statin new users or
prevalent users; (3) men or women; and (4) age <65 years
or 65 years. A two-sided p < 0.05 was considered statis-
tically significant.
Sensitivity analysis to assess unmeasured
confounding effect by smoking using external data
The information of relevant lifestyle factors, such as
smoking, altering the risk of lung cancer was usually not
recorded in the NHI claims database preventing us from
direct adjustment for their possible confounding effects.
Therefore, to investigate the potential impact of smoking,
we analyzed data from the National Health Interview Sur-
vey (NHIS) in Taiwan 2005 to quantify the imbalance in
proportion of smokers between statin users and nonusers.
This was a cross-sectional survey of a national representa-
tive sample based on a multistage complex design.20 The
survey was conducted by trained interviewers under a
standardized protocol and included demographic charac-
teristics, health status and behavior, medical utilization,
and other relevant information. A total of 27,726 partici-
pants completed the survey with the response rate of
80.6%. Participants were defined as having diabetes if they
reported that they had been told by a doctor or healthcare
professional that they had diabetes. Question items of
whether the interviewees are currently receiving lipid-
lowering medication and their smoking history were used
to calculate prevalence of smoking status (ever, never) in
statin users and nonusers. We further conducted quantita-
tive sensitivity analysis to understand how the strength of
an unmeasured confounder, i.e., smoking status in this
study, and imbalance among statin users and nonusers af-
fects the observed association.21 Because the relationship
of smoking and lung cancer varies with ethnicity, we
explored the impact of smoking with a range of RRCD (as-
sociation of smoking and lung cancer: 6e17 for SCC,
1.5e5.0 for adenocarcinoma), which were estimated from
one recent meta-analysis.22 Furthermore, we addressed the
potentially differential relation by sex. The relative risk of
11.98 for males and 8.97 for females for smoking-SCC as-
sociation, and the relative risk of 3.55 for males and 2.32
for females for smoking-adenocarcinoma association were
used as the best guess for RRCD.
22
Results
During the period from January 1, 2000 to December 31,
2000, a total of 640,173 patients were initially identified by
the algorithm and 596,812 patients were included in the
analysis (Fig. 1). These patients were followed for a median
Figure 1 Study flow.
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died, whereas only 1566 (0.2%) were lost to follow-up due
to discontinuation from or drop-out of health insurance.
In the diabetic cohort, 270,564 (45%) patients had ever
received statins. The most commonly prescribed statin in
terms of cumulative usage was atorvastatin (29.7%), fol-
lowed by simvastatin (20.6%), lovastatin (17.7%), fluvastatin
(12.7%), pravastatin (10.8%), and rosuvastatin (8.4%).
Because the NHI treatment guideline on dyslipidemia re-
quests that patients attaining the targeted goal of choles-
terol reduction either discontinued or titrated down to the
minimal dosage of statin therapy, the mean cumulative
duration was 590 days among the statin users during the
study period.
A total of 60,969 statin users and 535,843 statin nonusers
were identified in the diabetic cohort in 2000. As compared
with statin nonusers, statin users were more likely to be fe-
male, at low socioeconomic status, and have cardiovascular
disease, cerebrovascular disease, diabetic long-term compli-
cations, or chronic kidney disease. Statins users were also
more likely to receive metformin, glinides, a-glucosidaseinhibitors, insulin, antihypertensive agents, aspirin, and
fibrates during the 12-month period before the initiation of
statin therapy (Table 1).Lung cancer risk in statin users estimated from the
NHI claims database
A total of 1182 incident lung SCC cases and 2345 lung
adenocarcinoma cases were identified. In the univariate
analyses, use of statin as a class was found to have a
negative association with SCC incidence, but not for
adenocarcinoma. After controlling for potential confound-
ing variables, a significantly decreased risk of SCC incidence
was found for statin use at any time (HR, 0.69; 95% CI,
0.60e0.81; Table 2). The protective effects were evident
for high and intermediate cumulative dosage and for cu-
mulative treatment duration 1 year, 1e2 years, and 2e3
years with a potential durationeresponse relationship. Risk
estimates were similar between prevalent and newly-
diagnosed type 2 diabetes patients, prevalent and new
Table 1 Characteristics, comorbidities, and medication
use among statin users and nonusers in type 2 diabetic pa-
tients in 2000.
Statin
nonusers
(n Z
535,843)
Statin
users
(n Z
60,969)
p
Mean age, y (SD) 61.96
(11.91)
62.09
(10.61)
0.004
Female 50.63 59.44 <0.001
Socioeconomic status (monthly income in New Taiwan
Dollars)
17,280 50.92 55.87 <0.001
17,281e22,800 34.09 28.59
22,801e28,800 4.91 4.96
28,801e36,300 3.52 3.68
36,301e45,800 3.14 3.27
>45,800 3.42 3.62
Comorbidities
Cardiovascular disease 65.08 78.97 <0.001
Peripheral vascular
disease
6.84 6.63 0.05
Cerebrovascular
disease
14.62 19.03 <0.001
Retinopathy 9.44 13.90 <0.001
Neuropathy 22.31 25.04 <0.001
Nephropathy 30.88 35.89 <0.001
Depression 3.76 4.47 <0.001
Chronic kidney disease 3.79 6.16 <0.001
Chronic liver disease 17.46 16.01 <0.001
Chronic lung disease 19.98 18.66 <0.001
Charlson’s Index 2.38 
1.74
2.62 
1.86
<0.001
Medication use prior to cancer diagnosis
Metformin 61.76 65.37 <0.001
Sulfonylurea 81.15 79.75 <0.001
Glinides 0.24 0.36 <0.001
Alpha-glucosidase
inhibitors
1.82 3.16 <0.001
Mean number of oral
antidiabetic agents
1.46 
0.76
1.50 
0.78
<0.001
Short-acting human
insulin
12.47 13.92 <0.001
Aspirin 23.48 40.08 <0.001
ACE inhibitors 32.45 45.29 <0.001
Angiotensin receptor
blockers
8.21 17.68 <0.001
Beta-blockers 31.15 43.05 <0.001
Calcium channel
blockers
42.42 56.42 <0.001
Fibrates 9.52 26.83 <0.001
Data are presented as % or mean  SD, unless otherwise indi-
cated.
ACE Z angiotensin-converting enzyme; SD Z standard devia-
tion.
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association was found for any use of statin and adenocar-
cinoma (HR, 0.97; 95% CI, 0.88e1.07), or in any of the dose
and duration category (Table 2).In the analysis examining the lung cancer risk of indi-
vidual statin, pravastatin (HR, 0.64; 95% CI, 0.45e0.90),
lovastatin (HR, 0.74; 95% CI, 0.58e0.95), and atorvastatin
(HR, 0.78; 95% CI, 0.63e0.97) were associated with a
significantly reduced risk of SCC (Table 4). The number of
cancer cases exposed to individual statin was too small to
allow us to further evaluate the potential doseeresponse
and durationeresponse relationships.
Sensitivity analysis
Among the 27,726 participants that completed the NHIS,
there were 1073 individuals who had a physician-confirmed
diagnosis of diabetes and were aged 30 years or older. Of
the 376 participants with complete records on lipid-
lowering medications and smoking history, the proportion
of smokers among statin users and nonusers was 24% and
35%, separately. For lung SCC (RRCD of 6e15) and given the
observed relation of 0.69 for statin as a class and 0.64 for
pravastatin, the fully adjusted RR would be 0.86e0.94 and
0.80e0.87, individually. Considering a specific RRCD of
11.98 for males and 8.97 for females, the fully adjusted RR
would be 0.92 for males and 0.90 for females for statin as a
class. For lung adenocarcinoma (RRCD of 1.5e5.0) and given
the observed relation of 0.97 for statin as a class and 1.02
for pravastatin, the fully adjusted RR would be 1.02e1.19
and 1.07e1.25, separately. Given a specific RRCD of 3.55 for
males and 2.32 for females, the corresponding adjusted RR
would be 1.14 for males and 1.08 for females for statin as a
class (Fig. 2).
Discussion
The results of this study demonstrate that statin use was
not associated with occurrence of lung adenocarcinoma.
However, the seemingly negative association between
statin use and SCC incidence is mostly attributed to a lower
incidence of smoking in those taking statin.
Diabetes has been linked with an increased risk of can-
cer occurrence.13,14 Statin is widely used in diabetic pa-
tients; however, its effect on cancer incidence has not been
determined. Therefore, it is important to explore the risk
of statin associated with cancer in this vulnerable popula-
tion. Our findings of a neutral association between statin
and lung cancer were comparable to those of recent re-
ports. Two large-scale studies demonstrated that long-term
use of statin is not associated with overall cancer or lung
cancer incidence.23,24 Also, two meta-analyses of observa-
tional studies found no association between statin use and
risk of lung cancer.25,26
However, there are still controversies concerning this
association. A cohort study conducted in northern Califor-
nia showed an increased risk of lung cancer in women,
which could be partially attributable to their smoking
habits.27 Reciprocally, other US studies reported a reduc-
tion in the risk of lung cancer.7,28 Apart from the above-
mentioned time-window bias and immortal time bias,
smoking information is not uniformly collected in health-
care databases or medical records and accordingly its
strong confounding effect was not fully adjusted for in the
cohorts and caseecontrol studies.29,30 Recently, due to the
Table 2 Risk of lung adenocarcinoma and squamous cell cancer (SCC) associated with statins use in type 2 diabetic patients.
Adenocarcinoma Squamous cell cancer
Number
of cases
Total persone
days
Crude HR
(95% CI)
Adjusted HR
(95% CI)a
p Number
of cases
Total
persone
days
Crude HR
(95% CI)
Adjusted HR
(95% CI)b
p
Nonuse 1640 2,549,885 Reference Reference 927 1,270,530 Reference Reference
Ever use 705 695,862 1.00
(0.91e1.09)
0.97
(0.88e1.07)
0.50 255 244,784 0.67
(0.58e0.78)
0.69
(0.60e0.81)
<0.01
Cumulative dosagec
High 174 180,722 0.98
(0.84e1.15)
0.98
(0.83e1.15)
0.79 55 62,695 0.58
(0.44e0.76)
0.64
(0.48e0.85)
<0.01
Intermediate 331 335,150 0.93
(0.83e1.06)
0.92
(0.81e1.04)
0.17 116 108,131 0.61
(0.50e0.74)
0.63
(0.52e0.76)
<0.01
Low 200 179,990 1.13
(0.97e1.31)
1.05
(0.90e1.22)
0.52 84 73,958 0.89
(0.81e1.11)
0.84
(0.67e1.06)
0.15
Cumulative duration
3 y 129 78,792 0.99
(0.82e1.19)
1.00
(0.83e1.21)
1.00 37 22,057 0.69
(0.49e0.96)
0.74
(0.55e1.09)
0.14
2e3 y 81 69,030 0.99
(0.79e1.24)
0.98
(0.78e1.24)
0.89 21 19,449 0.50
(0.33e0.78)
0.55
(0.35e0.85)
<0.01
1e2 y 135 128,473 0.93
(0.77e1.11)
0.91
(0.76e1.09)
0.32 45 44,620 0.58
(0.43e0.78)
0.61
(0.45e0.83)
<0.01
1 y 360 419,567 1.03
(0.92e1.15)
0.97 (0.86e1.10) 0.66 152 158,658 0.73
(0.62e0.87)
0.73
(0.61e0.87)
<0.01
CI Z confidence interval; DDD Z defined daily dose; HR Z hazard ratio.
a Multivariable model including time-varying use of statins, fibrates, short-acting human insulin, metformin, glinides, chronic lung
disease, calcium channel blockers, cerebrovascular disease, angiotensin-converting-enzyme inhibitors, aspirin, and retinopathy.
b Multivariable model including time-varying use of statins, fibrates, short-acting human insulin, metformin, glinides, chronic lung
disease, and retinopathy.
c Cumulative dosage for statin use was categorized as high (>365 DDD for SCC, >400 DDD for adenocarcinoma), intermediate (109e365
DDD for SCC, 117e400 DDD for adenocarcinoma), and low dose (<109 for SCC, <117 DDD for adenocarcinoma).
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use may be accompanied by an effort of smoking cessation.
Therefore, the observed protective effect of statin on
reducing lung cancer might be attributed to and
confounded by a concomitant reduction in smoking, as
demonstrated in our sensitivity analysis.
A caseecontrol study analyzing the Taiwan NHI database
reported a non-significantly decreased risk of lung cancer
for statin (adjusted odds ratio, 0.82; 95% CI, 0.58e1.15).31
Compared with our study, it did not manage the residual
confounding of smoking using external information. In
addition, it restricted to female populations and examined
the relationship with overall lung cancer rather than indi-
vidual cancer types. This may explain its slightly inconsis-
tent findings with our results. Furthermore, it is known that
the relationship of smoking and lung cancer varies with
cancer types, with a higher risk for SCC than for adeno-
carcinoma.22 Therefore, the confounding effect of smoking
will be more profound for SCC than for adenocarcinoma.
This may partially illustrate why the protective effect of
statin is observed on SCC rather than on adenocarcinoma
prior to when we performed the sensitivity analysis.
Besides the residual confounding effect by smoking,
other factors that may explain the putative association
between statin use and lung cancer occurrence reported
by previous studies include body mass index (BMI),
concomitant care, and detection bias. Furthermore, pa-
tients undergoing statin therapy may have highersocioeconomic status and receive a better quality of care.
They may take more frequent preventive health services
such as chest X-ray examinations which lead to a different
chance of lung cancer detection as compared with non-
users.32 However, in our study, the BMI (mean  standard
deviation, kg/m2) did not apparently differ between statin
users (26.4  3.9) and nonusers (25.5  4.3) based on in-
formation in the NHI program. Also, no substantial dif-
ference in socioeconomic status (using monthly income as
a proxy) was found among statin treatment groups, prob-
ably because the universal NHI program covers all Taiwa-
nese people regardless of income level. Another concern is
that most statin users are those who had cardiovascular or
cerebrovascular diseases and thus were at increased risk
of death due to these comorbidities such that competing
risk may play a role in the observed protective association.
However, we adjusted for confounding effects of comor-
bidities through the regression model, which may partially
minimize the impact of competing risk on the observed
negative association.
The universal and compulsory NHI program in Taiwan
offered the strength of low loss to follow-up rate in this
study. The highly accurate information on cancer occur-
rence and pathology verified by linkage through National
Cancer Registry allowed us to examine the association with
SCC and adenocarcinoma separately. Moreover, we used
time-varying instead of time-fixed analysis to reduce po-
tential immortal time bias.
Table 3 Risk of lung adenocarcinoma and squamous cell cancer associated with statins use among different subgroups of type
2 diabetes patients.
Adenocarcinoma Squamous cell cancer
Number
of cases
Total
persone
days
Crude HR
(95% CI)
Adjusted
HR
(95% CI)a
p Number
of cases
Total
persone
days
Crude HR
(95% CI)
Adjusted
HR
(95% CI)b
p
Newly
diagnosed
diabetic
patients
42 37,640 1.11
(0.77e1.61)
1.13
(0.77e1.67)
0.52 20 17,896 0.81
(0.49e1.35)
0.78
(0.46e1.32)
0.35
Prevalent
diabetic
patients
663 658,222 0.98
(0.89e1.08)
0.96
(0.87e1.06)
0.40 235 226,888 0.66
(0.57e0.77)
0.69
(0.59e0.80)
<0.01
Prevalent
statin
users
140 196,335 0.76
(0.64e0.91)
0.71
(0.59e0.85)
<0.01 48 66,449 0.46
(0.34e0.62)
0.48
(0.36e0.65)
<0.01
New statin
users
565 499,527 1.01
(0.91e1.11)
0.99
(0.89e1.10)
0.78 207 178,335 0.69
(0.59e0.81)
0.72
(0.61e0.84)
<0.01
Men 287 284,792 0.97
(0.84e1.12)
0.99
(0.86e1.15)
0.90 208 198,480 0.78
(0.66e0.91)
0.81
(0.69e0.96)
0.01
Women 418 411,070 1.02
(0.90e1.16)
0.96
(0.84e1.10)
0.53 47 46,304 0.78
(0.55e1.12)
0.74
(0.51e1.07)
0.11
Age 65 y 392 381,541 0.97
(0.86e1.09)
0.96
(0.85e1.10)
0.58 170 165,379 0.70
(0.59e0.83)
0.73
(0.61e0.87)
<0.01
Age <65 y 313 314,321 1.13
(0.97e1.30)
1.07
(0.92e1.26)
0.37 85 79,405 0.71
(0.55e0.91)
0.69
(0.53e0.91)
<0.01
CI Z confidence interval; HR Z hazard ratio.
a Multivariable model including time-varying use of statins, fibrates, short-acting human insulin, metformin, glinides, chronic lung
disease, calcium channel blockers, cerebrovascular disease, angiotensin-converting-enzyme inhibitors, aspirin, and retinopathy.
b Multivariable model including time-varying use of statins, fibrates, short-acting human insulin, metformin, glinides, chronic lung
disease, and retinopathy.
Table 4 Risk of lung adenocarcinoma and squamous cell cancer associated with use of different statins in type 2 diabetic
patients.
Adenocarcinoma Squamous cell cancer
Number
of cases
Total
persone
days
Crude HR
(95% CI)
Adjusted HR
(95% CI)a
p Number
of cases
Total
persone
days
Crude HR
(95% CI)
Adjusted HR
(95% CI)b
p
Nonuse 1640 2,549,885 Reference Reference 927 2,549,885 Reference Reference
Simvastatin 228 221,227 0.90
(0.78e1.05)
0.88
(0.76e1.01)
0.08 82 82,993 0.80
(0.63e1.01)
0.81
(0.64e1.02)
0.07
Lovastatin 227 232,761 1.05
(0.92e1.21)
1.06
(0.92e1.22)
0.43 72 66,181 0.73
(0.57e0.93)
0.74
(0.58e0.95)
0.02
Pravastatin 136 131,218 1.01
(0.84e1.21)
1.02
(0.85e1.22)
0.84 35 30,768 0.61
(0.43e0.86)
0.64
(0.45e0.90)
0.01
Fluvastatin 158 147,910 1.08
(0.91e1.27)
1.06
(0.90e1.26)
0.50 51 48,414 0.85
(0.63e1.13)
0.87
(0.65e1.16)
0.35
Atorvastatin 342 272,655 1.03
(0.91e1.17)
0.99
(0.87e1.13)
0.93 112 93,004 0.79
(0.64e0.98)
0.78
(0.63e0.97)
0.02
Rosuvastatin 37 10,730 1.01
(0.72e1.41)
1.01 (0.72e1.41) 0.97 9 2715 0.72
(0.37e1.41)
0.72
(0.37e1.42)
0.35
CI Z confidence interval; HR Z hazard ratio.
a Multivariable model including time-varying use of statins, fibrates, short-acting human insulin, metformin, glinides, chronic lung
disease, calcium channel blockers, cerebrovascular disease, angiotensin-converting-enzyme inhibitors, aspirin, and retinopathy.
b Multivariable model including time-varying use of statins, fibrates, short-acting human insulin, metformin, glinides, chronic lung
disease, and retinopathy.
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Figure 2 Sensitivity analysis of unmeasured confounding
effect by smoking using external data.
DM, statins, smoking and lung cancer 947There are limitations in this study. First, the information
of several potential confounding factors, such as smoking,
BMI, and physical activities, cannot be obtained from the
healthcare claims database. Although we did adjust for
some of major factors and use sensitivity analysis to explore
the “true” association, residual confounding effect could
possibly exist. Second, we did not explore the mechanistic
background of the pleiotropic effect of statins. Numerous
laboratory studies suggest that statins might inhibit lung
cancer growth, but the results from clinical trials are
discouraging.33,34 Finally, as the mean daily dosage among
the study patients was relatively low due to low persistency
rate on statin therapy, our findings would probably not
generalize to the risk associated with higher dosage of
statin use for a longer treatment duration.
In conclusion, there is no statistically significant associ-
ation between statin use and lung adenocarcinoma in the
diabetic patients in Taiwan. The negative association be-
tween statins and SCC could be largely attributed to the
confounding effect of cigarette smoking. This result has
demonstrated the importance of fully adjusting for the
confounding effect of smoking when the association be-
tween statin use and lung cancer is explored from large-
scale healthcare databases as a cohort or a case-control
study.Acknowledgments
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